Orthocell Limited (ASX: OCC) is a pharmaceutical company based in Australia. The company specialises in regenerative medicine, regeneration of tissue and restoring mobility, offering new techniques to the regeneration of tendon, repair, soft tissue injuries and cartilage.
Orthocell Limited announced that it has received pleasing results in the patients’ progress on the completion of first four patients surgery using CelGro® under nerve regeneration clinical trial. The trial is reportedly being undertaken by Dr Alex O’Beirne of St John of God Subiaco Hospital and Professor Ming Hao Zheng of the University of Western Australia.
The response was so compelling that patients have regained the sensation of affected limbs and muscle, thereby returning to work, sports and daily activities. On this news, Orthocell’s stock surged 356.522% to close at $0.525 on 8 May 2019.
Dr Alex O’Beirne stated that the level of severity of nerve injuries in patients is such that it would not have been regained without microsurgery. But the use of CelGro® has resulted in re-joining of severe nerves, improved strength and quality of the repair, making surgery easier.
The feedback shared by Dr Alex O’Beirne for the drug is promising as he said that the progress of the patients and regaining use of affected limbs has been faster than his expectation and still showing improvements.
Four patients treated with the drug had previously suffered severe injuries following motor vehicle, sport and work-related incidents, consequential to impaired use of limbs and complete paralysis. Due to significant pain caused by injuries, patients were unable to perform daily activities at work, home or sport.
A review of clinical results 24 months after nerve regeneration treatment with CelGro® has shown that Celgro® guides and supports nerve re-generation in severely damaged peripheral nerves of hands and upper limb. The trials witnessed muscle functions returning as well as sensation regained in the patients.
The study of the trial includes 20 patients with nerve injuries that require surgeries. Out of the 20 patients, CelGro® has treated 15 (75%) patients positively with recruitment expected be completed by Q2 CY2019. British Medical Research Council Grading System was used to evaluate the muscle function/power following CelGro® nerve regeneration treatment and had a score of 0 to 5. A score of 5 indicates the results are optimal whereas 0 indicates an inability to contract muscles. Moreover, the sensory function was also assessed in the newly regenerated muscles using static and moving two-point discrimination test.
As per the company’s information, first four patients scored a 4 out of 5 after the treatment with CelGro® which represents an 83% improvement; however, the same patients scored 0 out of 5 before the treatment with Celgro®. The positive results indicate the effectiveness of treatment using Celgro® as well as tensionless repair of peripheral nerves to enhance existing surgical procedures.
In the US, over 20 million people suffer from peripheral nerve injuries resulting from the motor vehicle, sporting or work-related incidents annually. Artificial conduits and synthetic sheaths used in exiting surgeries require sutures. To address the disadvantages of suturing, Orthocell designed CelGro® with handling characteristics to assist surgeons perform complex reconstructive surgical procedures and enable the tensionless repair of soft tissue defects.
The company eyes CelGro® to be worth more than US$1.1 billion per annum with ~700,000 procedures that could use CelGro® completed each year.